A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease; A Prospective, Randomized, Parallel, Open-Label, Single-center, Phase IV Clinical Trial
Sponsor: Yuhan Corporation
This PHASE4 trial investigates Blood Viscosity and Coronary Artery Disease and is currently completed. Yuhan Corporation leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Jan 2025 — Feb 2025 [monthly]
Completed PHASE4
-
Dec 2024 — Jan 2025 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE4
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Yuhan Corporation
For direct contact, visit the study record on ClinicalTrials.gov .